Share
Rentschler Biopharma offers a complete range of services, including bioprocess development to cGMP manufacturing, for the clinical supply of AAV at its Stevenage facility. Credit: Rentschler Biopharma SE.

Rentschler Biopharma has collaborated with Ikarovec for expediting the new gene therapies to treat ophthalmic disease.

Under the deal, Rentschler Biopharma’s ATMP facility in Stevenage, UK, will undertake the bioprocess development of adeno-associated virus (AAV) material.

Related Company Profiles

View all

The AAV material will be used for the planned pre-clinical testing of the new gene therapy of Ikarovec to treat geographic atrophy, an advanced form of age-related macular degeneration that may result in the progressive and irreversible destruction of retinal tissue.

Ikarovec chief scientific officer Dr Katie Binley said: “We are delighted to collaborate with Rentschler Biopharma on our lead programme.

“As we look to find new and better ways to treat ophthalmic diseases, we want to get it right and ensure that our product candidates can be scaled up appropriately for each development stage and, ultimately, for commercialisation.

“Thus, it is critical to work with a team that has strong AAV experience in our field and that will be a true partner every step of the way.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company is developing new and differentiated gene therapies for the treatment of serious, but common eye diseases.

Rentschler Biopharma chief scientific officer Dr Christian Schetter said: “With Rentschler Biopharma’s ATMP offering, we aim to address an important gap in specific support for innovative, early-stage cell and gene therapy programmes.”

The company is a global contract development and manufacturing organisation (CDMO) for biopharmaceuticals.

It offers complete a range of services, including bioprocess development to cGMP manufacturing, for the clinical supply of AAV at its Stevenage facility.

Rentschler Biopharma integrates early process development strategies with accelerated timelines.

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.